IRIDEX CORP

Listed Company

IRIXCIK 0001006045NasdaqNon-AcceleratedSmaller ReportingElectromedical & Electrotherapeutic ApparatusDelawareFY ends Jan 3

Period

FY 2025

Revenue

$52.67M

Net Income

$-4.44M

Total Assets

$29.15M

Equity

$4.92M

Shares Out

17.41M

Op. Cash Flow

$-2.12M

IRIX$0.93−29.19% · past yearDBEQ Basic

Daily closing prices

Business

IRIDEX Corporation is an ophthalmic medical technology company developing and commercializing laser systems and consumable probes for treating glaucoma and retinal diseases. The company offers laser consoles (Cyclo G6, IQ, OcuLight, and PASCAL systems) incorporating proprietary MicroPulse and Endpoint Management technologies, along with delivery devices and single-use disposable probes. IRIDEX generates recurring revenue through consumable probe sales and service contracts, distributing primarily through a direct sales force in the United States and Germany and through independent distributors internationally.

Summary from 10-K filed 2026-04-02

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	53	49	52	57	54
Cost of revenues	33	29	30	32	31
Gross profit	19	20	22	25	23
Research and development	4	5	7	7	7
Sales and marketing	10	13	16	18	15
General and administrative	8	10	9	8	9
Total operating expenses	22	28	32	33	30
Loss from operations	−3	−8	−10	−8	−8
Other expense, net	−2	−540,000	527,000	60,000	2
Loss from operations before provision for income taxes	−4	−9	−9	−7	−5
Provision for income taxes	57,000	68,000	90,000	65,000	40,000
Net loss	−4	−9	−10	−8	−5
Basic (per share)	−0.26	−0.54	−0.59	−0.47	−0.34
Diluted (per share)	−0.26	−0.54	−0.59	−0.47	−0.34
Basic (shares)	17	16	16	16	15
Diluted (shares)	17	16	16	16	15

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	6	2	7	14	24
Accounts receivable, net	8	6	7	6	7
Receivable from related party	2	2	3	4	—
Inventories	8	11	10	11	8
Prepaid expenses and other current assets	2	2	856,000	1	1
Total current assets	25	24	27	36	42
Property and equipment, net	58,000	115,000	351,000	462,000	428,000
Intangible assets, net	984,000	1	2	2	2
Goodwill	965,000	965,000	965,000	965,000	965,000
Operating lease right-of-use assets, net	768,000	2	3	2	3
Other long-term assets	1	1	1	1	271,000
Total assets	29	29	34	42	49
Accounts payable	5	7	4	4	3
Payable to related party	117,000	609,000	228,000	15,000	—
Accrued compensation	2	2	2	2	3
Accrued expenses	608,000	477,000	2	2	2
Convertible note payable, current	0	2	0	—	—
Other current liabilities	2	2	1	968,000	1
Deferred revenue, current	2	2	2	2	2
Operating lease liabilities, current	699,000	1	995,000	1	927,000
Total current liabilities	13	17	13	12	13
Deferred revenue	7	8	10	12	11
Operating lease liabilities	98,000	811,000	2	732,000	2
Convertible note payable	4	1	0	—	—
Other long-term liabilities	387,000	314,000	164,000	26,000	25,000
Total liabilities	24	27	25	25	25
Commitments and contingencies (Note 11)	—	—	—	—	—
Common stock, $0.01 par value: Authorized: 63,500,000 shares; Issued and outstanding 17,306,521 shares as of January 3, 2026 and 16,636,380 as of December 28, 2024	174,000	174,000	172,000	169,000	168,000
Additional paid-in capital	91	90	88	87	85
Accumulated other comprehensive income (loss)	−14,000	51,000	−52,000	−24,000	45,000
Accumulated deficit	−92	−88	−79	−70	−62
Total stockholders equity	5	2	10	17	23
Total liabilities and stockholders equity	29	29	34	42	49

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−4	−9	−10	−8	−5
Loss on inventory write-down	823,000	0	—	—	—
Loss on extinguishment of convertible note payable	1	0	—	—	—
Depreciation and amortization	523,000	584,000	1	485,000	803,000
Amortization of operating lease right-of-use assets	1	840,000	934,000	899,000	905,000
Accretion of original issue discount	58,000	146,000	0	—	—
Amortization of debt issuance costs	169,000	182,000	0	—	—
Stock-based compensation	775,000	1	2	2	2
Accounts receivable	−2	776,000	−254,000	196,000	639,000
Receivable from related party	511,000	484,000	612,000	−433,000	−3
Inventories	2	−911,000	644,000	−3	268,000
Prepaid expenses and other current assets	162,000	−1	612,000	−397,000	−341,000
Other long-term assets	270,000	2,000	−427,000	−1	−143,000
Accounts payable	−2	2	641,000	1	2
Payable to related party	−492,000	381,000	213,000	−612,000	627,000
Accrued compensation	668,000	53,000	−829,000	−744,000	1
Accrued expenses	131,000	−2	448,000	−25,000	588,000
Deferred revenue	−2	−2	−2	868,000	12
Operating lease liabilities	−1	−841,000	−924,000	−886,000	−1
Other liabilities	537,000	730,000	130,000	−129,000	—
Net cash used in operating activities	−2	−7	−7	−10	8
Acquisition of property and equipment	−143,000	−13,000	−109,000	−286,000	−213,000
Net cash used in investing activities	−143,000	−13,000	−109,000	−286,000	−6
Net proceeds from issuance of convertible note payable	4	3	0	—	—
Cash paid for debt issuance costs	0	−493,000	0	—	—
Proceeds for stock option exercises	0	4,000	82,000	21,000	217,000
Payments on convertible note payable	−4	−218,000	—	—	—
Proceeds from issuance of Series B convertible preferred stock	6	0	—	—	—
Taxes paid related to net share settlements of equity awards	−75,000	−58,000	−87,000	−94,000	−629,000
Net cash provided by financing activities	6	3	−5,000	−73,000	9
Effect of foreign exchange rate changes	−65,000	46,000	−29,000	−52,000	99,000
Net increase (decrease) in cash and cash equivalents	4	−5	−7	−10	12
Cash paid (refunded) during the period for income taxes	−22,000	15,000	53,000	73,000	15,000
Debt issuance cost	360,000	0	—	—	—
Issuance of common shares in conjunction with extinguishment of convertible note payable	250,000	0	—	—	—
ROU assets obtained with acquisition of operating lease	78,000	0	—	—	—
Issuance of incentive shares under convertible note payable	0	250,000	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is IRIDEX CORP's CIK number?

IRIDEX CORP's SEC CIK number is 0001006045 (1006045). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find IRIDEX CORP's SEC filings?

All of IRIDEX CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did IRIDEX CORP last report earnings?

IRIDEX CORP (IRIX) most recently filed an earnings 8-K with the SEC on May 19, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-230774). This is IRIDEX CORP's most recent earnings filing of record — not a forecast of its next earnings date.

What is IRIDEX CORP's most recent earnings 8-K?

IRIDEX CORP's latest earnings 8-K (Item 2.02) was filed May 19, 2026 under accession 0001193125-26-230774. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View IRIDEX CORP's latest earnings 8-K →
Look up any company's CIK number →